Short answer
Guardant Health, Inc. (GH) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation), Item 3.02 (Unregistered Sales of Equity Securities), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). $550M 0% convertible notes due 2032, expanding long-term financing without regular cash interest expense.
Guardant Health, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $550M 0% convertible notes due 2032, expanding long-term financing without regular cash interest expense
- $501.7M used to repurchase $395.2M of 2027 notes, reducing near-term refinancing risk
- Initial conversion price $208.95, 35.0% premium to $154.78 stock price, limiting immediate dilution risk
- $51.7M capped-call cost, with a $309.56 cap price designed to offset dilution up to that level
- Net proceeds approximately $538.3M, leaving roughly $36.6M before capped-call funding and cash-on-hand contribution
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 points investors to Item 1.01 for details on Guardant Health’s newly created financial obligation
- The obligation relates to the company’s indenture and notes, potentially affecting leverage, interest expense and future liquidity
Item 3.02 · Unregistered Sales of Equity Securities
- Convertible Notes sold privately under Section 4(a)(2) and Rule 144A, limiting initial availability to institutional investors
- Maximum 3,553,385 common shares issuable upon conversion, creating potential shareholder dilution
- Initial conversion rate 6.4607 shares per $1,000 principal amount, subject to anti-dilution adjustments
- Notes and conversion shares unregistered, restricting U.S. resale absent registration or an exemption
Item 8.01 · Other Events
- Proposed offering announced November 11, 2026, signaling planned capital raising by Guardant Health
- Offering pricing announced November 12, 2026, with terms in Exhibit 99.2
- Investors should assess dilution, proceeds and use of capital from the priced offering
Item EX-99.1 · Exhibit EX-99.1
- Proposed $500.0M convertible senior notes due May 15, 2032, plus $50.0M overallotment option
- Refinancing strategy: proceeds may repurchase a portion of 0% convertible notes due 2027
- Conversion terms, interest rate and initial conversion rate remain subject to pricing
- Capped calls intended to reduce conversion-related dilution, subject to a cap
- Remaining proceeds may support acquisitions, technology investments or general corporate purposes
Item EX-99.2 · Exhibit EX-99.2
- $500M 0% convertible notes due May 15, 2032, with potential $50M upsizing option
- Net proceeds approximately $489.3M, rising to $538.3M if fully upsized
- Approximately $395.2M of 2027 convertible notes targeted for cash repurchase, reducing near-term refinancing needs
- Initial conversion price approximately $208.95, a 35.0% premium to $154.78 share price
- $51.7M capped-call cost, with $309.56 cap price intended to limit conversion dilution but adding transaction expense
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Guardant Health, Inc. 8-K filings
Get the next GH 8-K as it lands
Follow GH for push alerts, or ask the research agent what this filing means.